Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Eton Pharmaceuticals (ETON) EBIT Margin: 2019-2025

Historic EBIT Margin for Eton Pharmaceuticals (ETON) over the last 6 years, with Sep 2025 value amounting to -6.07%.

  • Eton Pharmaceuticals' EBIT Margin fell 1100.00% to -6.07% in Q3 2025 from the same period last year, while for Sep 2025 it was -4.89%, marking a year-over-year increase of 424.00%. This contributed to the annual value of -6.66% for FY2024, which is 289.00% down from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' EBIT Margin is -6.07%, which was up 22.12% from -7.79% recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year EBIT Margin high stood at 45.08% for Q1 2021, and its period low was -754.45% during Q3 2021.
  • Its 3-year average for EBIT Margin is -9.28%, with a median of -7.79% in 2025.
  • Within the past 5 years, the most significant YoY rise in Eton Pharmaceuticals' EBIT Margin was 2,261,419bps (2021), while the steepest drop was 24,731,177bps (2021).
  • Quarterly analysis of 5 years shows Eton Pharmaceuticals' EBIT Margin stood at 21.57% in 2021, then plummeted by 907bps to 12.50% in 2022, then crashed by 1,918bps to -6.69% in 2023, then skyrocketed by 1,209bps to 5.40% in 2024, then plummeted by 1,100bps to -6.07% in 2025.
  • Its EBIT Margin stands at -6.07% for Q3 2025, versus -7.79% for Q2 2025 and -26.32% for Q1 2025.